LN-428Homo sapiens (Human)Cancer cell line

Also known as: LN428, LN 428

🤖 AI SummaryBased on 8 publications

Quick Overview

LN-428 is a human glioblastoma cell line with p53 mutations and resistance to chemotherapeutic agents.

Detailed Summary

LN-428 is a human glioblastoma cell line derived from a malignant glioma. It exhibits mutations in the p53 gene, specifically at codons 173 and 282, which may contribute to its resistance to certain chemotherapeutic agents. This cell line is commonly used in research to study multidrug resistance mechanisms and the role of p53 mutations in glioma progression. LN-428 has been utilized in studies investigating the effects of P-glycoprotein and MRP-mediated drug resistance, as well as in assessing the efficacy of novel therapeutic agents targeting p53 pathways. Its genetic profile makes it a valuable model for understanding the molecular basis of glioma resistance and for developing targeted therapies.

Research Applications

Multidrug resistance studiesp53 mutation analysisChemotherapy resistance mechanismsTargeted therapy development

Key Characteristics

p53 mutations at codons 173 and 282Resistance to chemotherapeutic agentsExpression of P-glycoprotein and MRPUsed in drug sensitivity assays

Generated on 6/20/2025

Basic Information

Database ID	CVCL_3959
Species	Homo sapiens (Human)
Tissue Source	Brain, left temporal lobe[UBERON:UBERON_0002808]

Donor Information

Age	48
Age Category	Adult
Sex	Male

Disease Information

Disease	Glioblastoma
Lineage	CNS/Brain
Subtype	Glioblastoma
OncoTree Code	GB

DepMap Information

Source Type	Academic lab
Source ID	ACH-000455_source

Known Sequence Variations

Type	Gene/Protein	Description	Zygosity	Note	Source
MutationSimple	TP53	p.Arg282Trp (c.844C>T)	Unspecified	-	PubMed=21173094, PubMed=1373872
MutationSimple	TP53	p.Val173Met (c.517G>A)	Unspecified	-	PubMed=11107048, PubMed=1933850, PubMed=1370612
Gene deletion	CDKN2A	-	Homozygous	Possible	PubMed=26870271

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin

X,Y

CSF1PO

D13S317

D16S539

D18S51

13,17

D21S11

30,31

D3S1358

16,17

D5S818

11,13

D7S820

8,12

D8S1179

12,13

FGA

20,25

Penta D

Penta E

14,16

TH01

8,9.3

TPOX

8,11

vWA

Gene Expression Profile

Gene expression levels and statistical distribution

Loading cohorts...

Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

DOI PubMed PMC

Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.

Golub T.R., Root D.E., Hahn W.C.

Sci. Data 1:140035-140035(2014).

DOI PubMed PMC

DNA fingerprinting of glioma cell lines and considerations on similarity measurements.

Hamou M.-F., Delorenzi M., Hegi M.E.

Neuro-oncol. 14:701-711(2012).

DOI PubMed PMC

Mechanisms of resistance of human glioma cells to Apo2 ligand/TNF-related apoptosis-inducing ligand.

Rieger J., Frank B., Weller M., Wick W.

Cell. Physiol. Biochem. 20:23-34(2007).

DOI PubMed

P-glycoprotein and multidrug resistance-associated protein mediate specific patterns of multidrug resistance in malignant glioma cell lines, but not in primary glioma cells.

Bahr O., Rieger J., Duffner F., Meyermann R., Weller M., Wick W.

Brain Pathol. 13:482-494(2003).

DOI PubMed PMC

CP-31398, a novel p53-stabilizing agent, induces p53-dependent and p53-independent glioma cell death.

Wischhusen J., Naumann U., Ohgaki H., Rastinejad F., Weller M.

Oncogene 22:8233-8245(2003).

DOI PubMed

Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines.

Van Meir E.G.

Brain Pathol. 9:469-479(1999).

DOI PubMed PMC

Predicting chemoresistance in human malignant glioma cells: the role of molecular genetic analyses.

Krajewski S., Reed J.C., von Deimling A., Dichgans J.

Int. J. Cancer 79:640-644(1998).

DOI PubMed

The human melanoma antigen-encoding gene, MAGE-1, is expressed by other tumour cells of neuroectodermal origin such as glioblastomas and neuroblastomas.

Rimoldi D., Romero P., Carrel S.

Int. J. Cancer 54:527-528(1993).

DOI PubMed

A simple p53 functional assay for screening cell lines, blood, and tumors.

Tada M., Van Meir E.G., Estreicher A., Iggo R.D.

Proc. Natl. Acad. Sci. U.S.A. 92:3963-3967(1995).

DOI PubMed PMC

Variant CD44 adhesion molecules are expressed in human brain metastases but not in glioblastomas.

Diserens A.-C., Van Meir E.G.

Cancer Res. 53:5345-5349(1993).

PubMed